Avenda's iQuest platform gets nod from FDA

By AuntMinnie.com staff writers

December 7, 2022 -- The U.S. Food and Drug Administration (FDA) has cleared Avenda Health's iQuest platform for use in prostate cancer management.

iQuest combines existing patient-specific diagnostic information and deep-learning algorithms to create a tailored map of where cancer is within the prostate. The platform enables a physician to make decisions that consider the cancer extent, rather than treating the whole organ, according to Avenda. Ultimately, the platform supports physicians and patients with treatment selection, planning, guidance, and follow-up, the company said.

In addition, Avenda noted that the company recently raised $10 million in series B funding to accelerate the use of iQuest and continue clinical evidence development.

Copyright © 2022 AuntMinnie.com
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking